Clinical trial
Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic…
NCT00399971 · Shenzhen Zhongxing Yangfan Biotech Co. Ltd., Industry · Unknown status
Key facts
| NCT number | NCT00399971 |
|---|---|
| Title | Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia |
| Official title | Phase I/II Study of An Ex Vivo Immunotherapy for Treatment of Idiopathic Aplastic Anemia |
| Lead sponsor | Shenzhen Zhongxing Yangfan Biotech Co. Ltd., Industry |
| Collaborators | The 12th Guangzhou Municipal Hospital Liu Hua Qiao Hospital |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Aplastic |
| Intervention type | Drug, Procedure |
| Interventions | Ex Vivo Immunotherapy, Ex vivo immunotherapy |
| Enrollment | 100 |
| Start date | Nov 1, 2002 |
| Primary completion | Jun 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Nov 15, 2006 |
| Last update posted | Nov 11, 2008 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: